Paper Details

  1. Home
  2. Paper Details

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.

Author: BrachmannCarrie Baker, CollinsHelen, DeiningerMichael W N, GuptaVikas, KawashimaJun, MesaRuben A, RiveraCandido E, SirhanShireen, VerstovsekSrdan, XinYan

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Momelotinib is a JAK1/JAK2 inhibitor that is effective in myelofibrosis patients. A phase 1/2 study of momelotinib with twice-daily dosing in 61 patients with myelofibrosis identified 200 mg twice daily as the optimal dose. The most frequent adverse events were diarrhea (45.9%), peripheral neuropathy (44.3%), thrombocytopenia (39.3%), and dizziness (36.1%). The response assessment demonstrated spleen response by palpation of 72% (36/50) and anemia response of 45% (18/40). The results suggest tolerability and a potential therapeutic activity of momelotinib for subjects.
Paper Details　
Original Abstract of the Article :
Momelotinib, a small-molecule inhibitor of Janus kinase 1 and Janus kinase 2, has demonstrated efficacy in myelofibrosis patients with 300 mg, once-daily dosing. This open-label, non-randomized, phase 1/2 study evaluated the safety and therapeutic benefit of momelotinib with twice-daily dosing. A to...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210237/

データ提供：米国国立医学図書館（NLM）

Momelotinib: A New Hope for Myelofibrosis Treatment

The field of [hematology] is constantly seeking new therapies to treat [myelofibrosis], a rare and debilitating blood disorder. This study explores the potential of [momelotinib], a [JAK1/JAK2 inhibitor], as a treatment for [myelofibrosis] patients. It's like searching for a cure in a vast desert of medical challenges; every step forward brings us closer to finding a solution.

Momelotinib's Potential as a Treatment

The researchers discovered that [momelotinib] administered twice daily was well-tolerated and showed [promising therapeutic activity] in [myelofibrosis] patients, including [improvement in spleen size, anemia, and symptoms]. This is like finding a spring of water in the desert; it offers hope for patients struggling with this challenging condition.

Managing Myelofibrosis

This research provides a valuable new option for treating [myelofibrosis] and offers hope for patients seeking relief from this debilitating disease. It's like finding a safe path through the desert; we need to explore all available options to ensure the best possible outcomes for patients.

Dr.Camel's Conclusion

This study is a beacon of hope for those struggling with [myelofibrosis]. It highlights the exciting possibilities of [targeted therapies] in treating complex blood disorders. The potential benefits of [momelotinib] are like a refreshing oasis in the desert of [myelofibrosis] research, offering a new path towards a healthier future for patients.

Date :
  1. Date Completed 2017-06-29
  2. Date Revised 2019-07-09
Further Info :

Pubmed ID

27634203

DOI: Digital Object Identifier

PMC5210237

Related Literature

Article Analysis
・Effects of momelotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.